Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$387M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$332M |
| 3 |
ServiceNow
NOW
|
+$265M |
| 4 |
New York Times
NYT
|
+$189M |
| 5 |
MXIM
Maxim Integrated Products
MXIM
|
+$152M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$456M |
| 2 |
IPHI
INPHI CORPORATION
IPHI
|
+$311M |
| 3 |
IQVIA
IQV
|
+$278M |
| 4 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$277M |
| 5 |
New Oriental
EDU
|
+$192M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.51% |
| 2 | Technology | 16.43% |
| 3 | Financials | 13.12% |
| 4 | Communication Services | 9.43% |
| 5 | Industrials | 7.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Protagonist Therapeutics
PTGX
$9.99B
| $105M | 0.43% |
2,329,680
-95,320
| -4% | -$3.15M |
|
|
BPMC
52
DELISTED
Blueprint Medicines
BPMC
| $99M | 0.4% |
1,125,000
+430,209
| +62% | +$39.4M |
|
|
APLS
53
DELISTED
Apellis Pharmaceuticals
APLS
| $98M | 0.4% |
1,550,000
-625,000
| -29% | -$32.3M |
|
|
GBIO
54
DELISTED
Generation Bio
GBIO
| $94.2M | 0.38% |
350,000
+22,950
| +7% | +$6.87M |
|
55
Enanta Pharmaceuticals
ENTA
$392M
| $87.8M | 0.36% |
1,995,000
| – | – |
|
56
Revolution Medicines
RVMD
$44.9B
| $79.3M | 0.32% |
2,500,000
+890,270
| +55% | +$31.1M |
|
57
PG&E
PCG
$38.8B
| $74.2M | 0.3% |
7,292,042
| – | – |
|
|
KRTX
58
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $71.8M | 0.29% |
630,000
-45,000
| -7% | -$5.26M |
|
59
Agios Pharmaceuticals
AGIO
$1.98B
| $63.9M | 0.26% |
1,160,000
-90,000
| -7% | -$5.03M |
|
|
CHNG
60
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $63.1M | 0.26% |
2,738,600
+1,285,000
| +88% | +$29.6M |
|
|
BRMK
61
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $62.3M | 0.25% |
5,880,000
-1,290,213
| -18% | -$13.7M |
|
|
PLYA
62
DELISTED
Playa Hotels & Resorts
PLYA
| $62.1M | 0.25% |
8,352,553
-6,642,314
| -44% | -$49M |
|
|
ARNA
63
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $58M | 0.24% |
850,000
| – | – |
|
|
ATTO
64
DELISTED
Atento S.A.
ATTO
| $57.2M | 0.23% |
2,230,357
| – | – |
|
65
Cytokinetics
CYTK
$10.7B
| $56.9M | 0.23% |
2,876,000
+376,000
| +15% | +$8.83M |
|
66
Natera
NTRA
$47.9B
| $56.8M | 0.23% |
+500,000
| New | +$51.1M |
|
|
PFPT
67
DELISTED
Proofpoint, Inc.
PFPT
| $52.9M | 0.22% |
+304,500
| New | +$49.4M |
|
68
Ascendis Pharma A/S
ASND
$16.6B
| $49.3M | 0.2% |
375,000
-625,000
| -63% | -$83.3M |
|
|
HZNP
69
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $46.8M | 0.19% |
+500,000
| New | +$46M |
|
70
Avantor
AVTR
$9.78B
| $46.3M | 0.19% |
+1,305,000
| New | +$42.2M |
|
71
Gulfport Energy Corp
GPOR
$3.07B
| $45.1M | 0.18% |
+697,444
| New | +$44.7M |
|
|
ZGNX
72
DELISTED
Zogenix, Inc.
ZGNX
| $38.9M | 0.16% |
2,250,000
| – | – |
|
|
RDUS
73
DELISTED
Radius Health, Inc.
RDUS
| $38.4M | 0.16% |
2,107,400
| – | – |
|
|
KYNB
74
Kyntra Bio
KYNB
$30.4M
| $38.3M | 0.16% |
57,557
-9,791
| -15% | -$5.64M |
|
75
BioAtla
BCAB
$5.3M
| $38.2M | 0.16% |
18,043
-11,798
| -40% | -$26.7M |
|
Similar funds
Thomas Steyer's Q2 2021 Portfolio in Review
As of Q2 2021, Thomas Steyer held 397 positions worth $24.5B, up 22% from $20.1B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Thomas Steyer deployed $2.47B of net new capital in Q2 2021, opening 164 new positions and adding to 36 existing holdings. Its largest new stake was Nuance Communications, Inc.: 7,337,500 shares worth $399M.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 36% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Alphabet (Google) Class C, an estimated $456M trimmed.
- Thomas Steyer's largest Q2 2021 buy was Nuance Communications, Inc.: 7,337,500 shares worth $399M.
- Thomas Steyer added most to Alexion Pharmaceuticals in Q2 2021, an estimated $332M increase.
- Thomas Steyer's biggest Q2 2021 reduction was Alphabet (Google) Class C, cutting an estimated $456M.
- Thomas Steyer fully exited INPHI CORPORATION in Q2 2021, selling an estimated $311M.
- Thomas Steyer's ten largest holdings make up 39% of its $24.5B portfolio in Q2 2021.
- Thomas Steyer opened 164 new positions and closed 100 in Q2 2021.
- Thomas Steyer's portfolio value rose 22% quarter-over-quarter to $24.5B.
Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.